Category: Accuray Inc.
A new survey of U.S. hip and knee surgeons adds to Wall Street analysts' confidence that the orthopedics market is looking up.
Wall Street analysts are predicting with increasing confidence that the U.S. orthopedics market is on the upswing following an industry survey suggesting a coming increase in procedure volumes.
A MEDACorp orthopedics survey of 65 U.S. hip and knee surgeons found improvements in 12-month procedure volume expectations and increased patient willingness for surgery, according to an investment note from Leerink Swann analyst Richard Newitter.
Abiomed says it hasn't heard of any Medicare reimbursement concerns, but a note from a Wall Street analyst sends shares down 6%.; also, Accuray teams up with the German Cancer Research Center; AngioDynamics closes the $335M Navilyst merger; athenahealth may be eyeing Epocrates; Covidien launches offering to pay off senior notes; plus, a Funding Roundup and analysts' ups and downs.
Abiomed (NSDQ:ABMD) slid 6% in late afternoon trading following a note from a Wall Street analyst warning about Medicare reimbursement concerns for the company's star Impella heart pumps.
Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year; plus, Q1 sales, earnings up for Henry Schein; LeMaitre Vascular's Q1 profits soar; Mindray's Q1 profits slide despite double-digit sales boost; Stereotaxis boosts Q1 sales, slashes losses; Steris profits spike in 2011; Symmetry Medical's Q1 bottom line plunges; Syneron boosts Q1 sales, losses widen; and more.
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
Shares of Accuray fall nearly 10% after the radiosurgery device maker lowers its sales forecast for the full year.
Accuray (NSDQ:ARAY) shares are down nearly 10% today as investors react to wider 3rd-quarter losses and a lower sales forecast for the rest of fiscal 2012.
The Sunnyvale, Calif.-based radiosurgery device maker reported losses of $14.9 million, or 21¢ per share, on sales of $101.8 million during the 3 months ended March 31.
Accuray CEO Euan Thomson tells MassDevice.com what it means to have a robotic device, the SEC probes Baxter on infusion pump recalls and St. Jude Medical's largest backer boosts stake by 30%.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you're still in the know with MassDevice +3.
Accuray CEO Euan Thomson discusses the finer points of robotic prostate cancer treatment and the motivation behind a head-to-head clinical trial pitting its CyberKnife radiosurgery system against Intuitive Surgical's da Vinci.
Early results from a 10-year follow-up of prostate cancer treatment suggests that prostatectomy offers minimal survival benefits compared with the "wait and see" approach in certain patients.
Early results from a long-term study of prostate cancer patients concluded that removal of the gland barely increased the likelihood for survival in patients with low-risk tumors, concluding that the surgical approach "may be neither necessary nor effective."
